A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer

Stephen Tang, Vidyalakshmi Sethunath, Nebiyou Y. Metaferia, Marina F. Nogueira, Daniel S. Gallant, Emma R. Garner, Lauren A. Lairson, Christopher M. Penney, Jiao Li, Maya K. Gelbard, Sarah Abou Alaiwi, Ji Heui Seo, Justin H. Hwang, Craig A. Strathdee, Sylvan C. Baca, Shatha AbuHammad, Xiaoyang Zhang, John G. Doench, William C. Hahn, David Y. TakedaMatthew L. Freedman, Peter S. Choi, Srinivas R. Viswanathan

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Androgen receptor (AR) signaling is the central driver of prostate cancer across disease states. While androgen deprivation therapy (ADT) is effective in the initial treatment of prostate cancer, resistance to ADT or to next-generation androgen pathway inhibitors invariably arises, most commonly through the re-activation of the AR axis. Thus, orthogonal approaches to inhibit AR signaling in advanced prostate cancer are essential. Here, via genome-scale CRISPR-Cas9 screening, we identify protein arginine methyltransferase 1 (PRMT1) as a critical mediator of AR expression and signaling. PRMT1 regulates the recruitment of AR to genomic target sites and the inhibition of PRMT1 impairs AR binding at lineage-specific enhancers, leading to decreased expression of key oncogenes, including AR itself. In addition, AR-driven prostate cancer cells are uniquely susceptible to combined AR and PRMT1 inhibition. Our findings implicate PRMT1 as a key regulator of AR output and provide a preclinical framework for co-targeting of AR and PRMT1 in advanced prostate cancer.

Original languageEnglish (US)
Article number110417
JournalCell reports
Issue number8
StatePublished - Feb 22 2022
Externally publishedYes

Bibliographical note

Funding Information:
We warmly thank Matthew Meyerson for helpful discussions and guidance. We are grateful for assistance from the DFCI Molecular Biology Core Facility, the Broad Institute and Dana Farber Cancer Institute Flow Cytometry Core Facilities, and the Broad Institute Genetic Perturbation Platform. This work was supported by the Department of Defense Prostate Cancer Research Program ( W81XWH-17-1-0358 to S.R.V.), the Prostate Cancer Foundation Young Investigator Award (to S.R.V.), the Prostate Cancer Foundation Challenge Award (to M.L.F), the American Cancer Society–AstraZeneca (PF-16-142-01-TBE, to J.H.H.), and the National Institutes of Health /National Cancer Institute ( R00 CA208028 , to P.S.C.; R01 CA193910 and R01 CA204954 to M.L.F.; and U01 CA176058 to W.C.H.). The graphical abstract was generated with BioRender.com .

Publisher Copyright:
© 2022


  • CRISPR screen
  • PRMT1
  • androgen receptor
  • prostate cancer
  • splicing
  • superenhancer
  • transcription

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.


Dive into the research topics of 'A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer'. Together they form a unique fingerprint.

Cite this